Our Vision

to relieve patient suffering and enhance lives

Using our novel R&D platform for the advancement of life-changing medicines, we focus on neurological and endocrine based diseases and disorders.

Learn More

Tardive Dyskinesia

is a potentially debilitating movement disorder.

We have a novel product approved for the treatment of adults with involuntary movements caused by exposure to dopamine receptor blocking agents.

Learn More

Endometriosis and Uterine Fibroids

Not all patients suffer the same way.

We are investigating a first-in-class, oral treatment option that addresses the chronic, intermittent, predictable and unpredictable symptoms common to Endometriosis and Uterine Fibroids.

Learn More

Tourette Syndrome

can mean life interrupted.

We are investigating a once-daily treatment for tics associated with Tourette syndrome.

Learn More

Congenital Adrenal Hyperplasia

requires life long care.

We are investigating a non-steroidal therapy for Classical CAH to treat the effects of life-long elevated androgens and the use of high-dose corticosteroids both of which can lead to the virilization of females, metabolic syndrome, bone loss, growth impairment, and Cushing's syndrome.

Learn More